Expert Review of Cardiovascular Therapy最新文献_第2页

Evaluating the shared risk factors between atherosclerotic cardiovascular disease and cancer: how significant is the link? 评估动脉粥样硬化性心血管疾病和癌症之间的共同危险因素：这种联系有多重要？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-07-01 DOI: 10.1080/14779072.2025.2527704

Brett Deng, Shubh Desai, Leslie Ynalvez, Moez Karim Aziz, Cezar Iliescu

{"title":"Evaluating the shared risk factors between atherosclerotic cardiovascular disease and cancer: how significant is the link?","authors":"Brett Deng, Shubh Desai, Leslie Ynalvez, Moez Karim Aziz, Cezar Iliescu","doi":"10.1080/14779072.2025.2527704","DOIUrl":"10.1080/14779072.2025.2527704","url":null,"abstract":"Introduction: Atherosclerotic cardiovascular disease (ASCVD) and cancer are the leading causes of death globally. While traditionally viewed as distinct, growing evidence reveals significant overlap in their risk factors and pathophysiology, suggesting a shared biological basis that warrants closer clinical and research attention.Areas covered: This review explores modifiable lifestyle and pathological risk factors that contribute to both ASCVD and cancer, including tobacco use, poor diet, physical inactivity, environmental toxins, hypertension, hyperlipidemia, obesity, insulin resistance, and sex hormone dysregulation. Mechanistically, these factors converge on common pathways such as chronic inflammation, oxidative stress, and hormonal imbalance, facilitating both atherogenesis and tumorigenesis. The paper also highlights how these shared mechanisms offer opportunities for unified prevention and treatment strategies.Expert opinion: Understanding these connections is critical for dual-risk stratification, prevention, and management strategies. Emerging approaches such as personalized medicine, leveraging genomic and biomarker data, and multidisciplinary care models that integrate cardiology and oncology expertise offer opportunities to optimize outcomes. Advances in multi-omics and targeted therapies promise to further elucidate the shared mechanisms, paving the way for innovative interventions. This comprehensive understanding highlights the need for integrated care to address the dual burden of ASCVD and cancer and improve patient outcomes.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular and periprocedural outcomes of endovascular intervention for acute limb ischemia at experienced urban versus rural centers in the US: national inpatient sample analysis 2016-2021. 美国经验丰富的城市和农村中心血管内介入治疗急性肢体缺血的心血管和围手术期结果：2016-2021年全国住院患者样本分析

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-28 DOI: 10.1080/14779072.2025.2527707

Yasar Sattar, Adishwar Rao, Sivaram Neppala, Himaja Dutt Chigurupati, Waleed Alruwaili, Hafeez Ul Hassan Virk, Fadi Saab, Jihad Mustapha, Abdullah Naveed Muhammad, Ramesh Daggubati, Akram Kawsara

{"title":"Cardiovascular and periprocedural outcomes of endovascular intervention for acute limb ischemia at experienced urban versus rural centers in the US: national inpatient sample analysis 2016-2021.","authors":"Yasar Sattar, Adishwar Rao, Sivaram Neppala, Himaja Dutt Chigurupati, Waleed Alruwaili, Hafeez Ul Hassan Virk, Fadi Saab, Jihad Mustapha, Abdullah Naveed Muhammad, Ramesh Daggubati, Akram Kawsara","doi":"10.1080/14779072.2025.2527707","DOIUrl":"https://doi.org/10.1080/14779072.2025.2527707","url":null,"abstract":"Background: Acute limb ischemia (ALI) is a critical vascular emergency marked by a sudden reduction in blood flow to the limb, significantly increasing amputation risk. Revascularization outcomes in urban versus rural areas have not been examined.Research design and methods: The National Inpatient Sample from 2016 to 2021 identified patients with ALI who underwent revascularization. Propensity score matching compared outcomes, analyzed using STATA version 18.Results: Of 85,760 hospitalizations for ALI receiving percutaneous revascularization 81,880 (95.5%) were in urban centers and 3,880 (4.5%) in rural facilities. Patients in urban hospitals showed higher mortality (4% vs. 2.7%), myocardial infarction (MI) (3.4% vs. 2.7%), cardiogenic shock (1.6% vs. 0.6%), cardiac arrest (6.5% vs. 5.9%), major adverse cardiovascular and cerebrovascular events (MACCE) (7.5% vs. 5.3%), mechanical circulatory support (1.1% vs. 0.5%), and acute kidney injury (18.5% vs. 15.4%). However, urban patients had lower intravascular ultrasound (IVUS) (3.4% vs. 6.5%), major amputation (6.3% vs. 7.8%), fasciotomy (1.8% vs. 2.2%), and major adverse limb events (MALE) (46.4% vs. 49.1%), with a significant difference of p < 0.01 compared to rural hospitals.Conclusions: Urban hospitals in the United States report elevated mortality rates and significant cardiovascular events in comparison to their rural counterparts.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How could a real-time adjusting anti-tachycardia pacing algorithm revolutionize treatment outcomes in patients with implantable cardioverter-defibrillators? 实时调节抗心动过速起搏算法如何彻底改变植入式心律转复除颤器患者的治疗结果？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-28 DOI: 10.1080/14779072.2025.2527720

Pierre Ollitrault, Jonaz Font, Virginie Ferchaud, Maxime Dupont, Arnaud Pellissier, Mayane Al Khoury, Paul-Ursmar Milliez, Laure Champ-Rigot

引用次数: 0

Electrocardiogram indicators of right ventricular dilation in repaired tetralogy of Fallot patients. 修复后法洛四联症患者右心室扩张的心电图指标。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-27 DOI: 10.1080/14779072.2025.2524566

Uchina Hiya, Tomoyuki Kabutoya, Kenta Fujimura, Kana Kubota, Yasushi Imai, Akiko Yokomizo, Mitsuru Seki, Kazuomi Kario

{"title":"Electrocardiogram indicators of right ventricular dilation in repaired tetralogy of Fallot patients.","authors":"Uchina Hiya, Tomoyuki Kabutoya, Kenta Fujimura, Kana Kubota, Yasushi Imai, Akiko Yokomizo, Mitsuru Seki, Kazuomi Kario","doi":"10.1080/14779072.2025.2524566","DOIUrl":"10.1080/14779072.2025.2524566","url":null,"abstract":"Background: Patients with surgically repaired tetralogy of Fallot (rTOF) often develop chronic pulmonary regurgitation (PR), necessitating pulmonary valve replacement (PVR). While cardiac MRI is crucial for PVR timing, its availability is limited. This study evaluates electrocardiographic (ECG) findings - specifically the R-wave amplitude in lead V1 (V1R) and the sum of the R-wave amplitude in lead V1 and the deepest S-wave amplitude in lead V5 or V6 (V1R + V5S or V6S) - as predictors of cardiac MRI findings.Patients and methods: We retrospectively analyzed 35 rTOF patients (mean age 34 ± 9 years; 60% male) who underwent cardiac MRI from 2019 to 2022, assessing correlations between ECG parameters (V1R, V1R + V5S or V6S, and QRS duration) and MRI findings (RVESVI and RVEDVI).Results: V1R showed significant correlation with RVESVI (r = 0.486, p = 0.003) and was notably higher in patients with RVESVI ≥ 80 mL/m2. A V1R cutoff of 20 mm identified RVESVI ≥ 80 mL/m2 with 67% sensitivity and 77% specificity.Conclusions: V1R on ECG may help predict the need for cardiac MRI, aiding in the timely PVR planning for rTOF patients.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-5"},"PeriodicalIF":1.8,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determining major adverse cardiovascular event risk of beta-blocker discontinuation after acute coronary syndromes. 确定急性冠状动脉综合征后β受体阻滞剂停药的主要不良心血管事件风险。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-01 Epub Date: 2025-06-19 DOI: 10.1080/14779072.2025.2520828

Nicolas Johner, Baris Gencer

{"title":"Determining major adverse cardiovascular event risk of beta-blocker discontinuation after acute coronary syndromes.","authors":"Nicolas Johner, Baris Gencer","doi":"10.1080/14779072.2025.2520828","DOIUrl":"10.1080/14779072.2025.2520828","url":null,"abstract":"Introduction: Beta-blocker therapy reduced mortality and cardiovascular events following acute coronary syndromes (ACS) in the pre-reperfusion era. In the contemporary era of early mechanical reperfusion and modern secondary prevention, the benefit of beta-blockers after ACS without reduced left ventricular ejection fraction (LVEF) has been questioned. This review was based on PubMed database searches from inception to January 2025.Areas covered: The recent REDUCE-AMI and ABYSS trials were the first adequately powered contemporary randomized trials evaluating beta-blockers after ACS without reduced LVEF. Contemporary observational evidence is also discussed. Implications for different LVEF categories (41-49% versus ≥ 50%), ACS subtypes, beta-blocker therapy duration, optimal dose, and interaction with other secondary prevention therapies are addressed.Expert opinion: We estimate that there is sufficient evidence to abandon routine beta-blocker prescription in post-ACS patients with preserved LVEF ≥ 50%. Beta-blocker prescription should be individualized with shared decision-making, balancing the risk of cardiovascular event against potential benefits of deprescription. Factors favoring beta-blocker discontinuation include adverse effects, polypharmacy, >1-3 years of stability post-ACS, and specific comorbidities (e.g. heart failure with preserved LVEF). Factors favoring beta-blocker prescription/continuation (besides established indications such as LVEF ≤ 40%, arrhythmias, angina, and refractory hypertension) include good tolerance, LVEF 41-49%, and non-adherence to other secondary prevention therapies.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"271-285"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bleeding risk assessment tools for patients with myocardial infarction: a comparative review and clinical implications. 急性心肌梗死出血风险评估工具：比较回顾和临床意义。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-01 Epub Date: 2025-06-26 DOI: 10.1080/14779072.2025.2520827

Kaeshaelya Thiruchelvam, Jonathan Than Chun Xin, Win Kit Law, Lyn Feng Lee, Xuen Bei Liew, Jia Le Lim, Olivia Sim Hui Min, Zhi Qi Tan, Chia Siang Kow

{"title":"Bleeding risk assessment tools for patients with myocardial infarction: a comparative review and clinical implications.","authors":"Kaeshaelya Thiruchelvam, Jonathan Than Chun Xin, Win Kit Law, Lyn Feng Lee, Xuen Bei Liew, Jia Le Lim, Olivia Sim Hui Min, Zhi Qi Tan, Chia Siang Kow","doi":"10.1080/14779072.2025.2520827","DOIUrl":"10.1080/14779072.2025.2520827","url":null,"abstract":"Introduction: Bleeding risk stratification tools are essential for optimizing ischemic protection while minimizing bleeding complications in patients with myocardial infarction, particularly for those undergoing percutaneous coronary intervention (PCI) or dual antiplatelet therapy.Areas covered: A structured search of PubMed, Scopus, and Web of Science was conducted for studies published from January 2005 to December 2024. This review evaluates traditional and novel bleeding risk models in MI management. Established tools like CRUSADE, ACUITY-HORIZONS, ACTION, and PRECISE-DAPT aid in predicting in-hospital and early post-discharge bleeding but have limitations in long-term risk assessment and adapting to modern PCI techniques. Emerging models - SWEDEHEART, ARC-HBR, CREDO-KYOTO, and BleeMACS - offer enhanced risk stratification by incorporating broader clinical variables and long-term bleeding predictors, improving their applicability to contemporary MI management.Expert opinion: Despite advancements, current models exhibit moderate predictive accuracy (c-statistics 0.70-0.80) and rely on static baseline factors, limiting real-time applicability. They also fail to integrate ischemic risk assessment, creating challenges in balancing thrombotic and bleeding risks. Future research should focus on AI-driven dynamic risk models, broader validation across diverse populations, and integrating bleeding and ischemic risk stratification into a unified framework. Embedding these tools into electronic health records will enhance clinical decision-making and improve patient outcomes.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"287-301"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Closing the prevention and diagnosis gap: how can we innovate early coronary heart disease identification in women with female-specific risk factors? 缩小预防和诊断差距：我们如何在具有女性特有危险因素的女性中创新冠心病早期识别？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-01 Epub Date: 2025-06-23 DOI: 10.1080/14779072.2025.2523929

Eva Sinha, Simone Marschner, Anushriya Pant, Sarah Zaman

引用次数: 0

How can clinicians help to facilitate more equitable cardiovascular healthcare? 临床医生如何帮助促进更公平的心血管保健？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-01 Epub Date: 2025-06-24 DOI: 10.1080/14779072.2025.2522219

Itamar S Santos

引用次数: 0

The overlooked cardiovascular burden of type 1 diabetes: from atherosclerosis to myocardial infarction. 被忽视的1型糖尿病心血管负担：从动脉粥样硬化到心肌梗死。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-01 Epub Date: 2025-06-18 DOI: 10.1080/14779072.2025.2522223

Jenyfer María Fuentes-Mendoza, Roger Gonzales-Valdivieso, Marcio Concepción-Zavaleta, Maicol Augusto Cortez Sandoval

引用次数: 0

Bleeding risk assessment tools in patients with atrial fibrillation taking anticoagulants: a comparative review and clinical implications. 房颤患者使用抗凝剂的出血风险评估工具：比较回顾和临床意义。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-06-01 Epub Date: 2025-07-08 DOI: 10.1080/14779072.2025.2523920

Chia Siang Kow, Feng Chen, Shawn Kai Jie Leong, Kai Yuan Tham, Li Ann Yeoh, Ze Ming Chew, Wen Jie Peh, Kaeshaelya Thiruchelvam

{"title":"Bleeding risk assessment tools in patients with atrial fibrillation taking anticoagulants: a comparative review and clinical implications.","authors":"Chia Siang Kow, Feng Chen, Shawn Kai Jie Leong, Kai Yuan Tham, Li Ann Yeoh, Ze Ming Chew, Wen Jie Peh, Kaeshaelya Thiruchelvam","doi":"10.1080/14779072.2025.2523920","DOIUrl":"10.1080/14779072.2025.2523920","url":null,"abstract":"Introduction: Bleeding risk assessment plays a critical role in the anticoagulation management for atrial fibrillation (AF), to balance stroke prevention with risk of major hemorrhage. Traditional bleeding risk models, such as HAS-BLED, ORBIT, and ATRIA, offer valuable insights but have limitations in predictive accuracy and clinical applicability. Recent advances in risk stratification have introduced novel models integrating biomarkers, genetic data, and artificial intelligence (AI)-driven algorithms to improve precision and individualized patient care.Areas covered: This review evaluates strengths and limitations of established bleeding risk assessment tools and explores emerging trends in predictive modeling. It discusses novel risk stratification models- DOAC Score, GARFIELD-AF, and HEMORR₂HAGES, which incorporate renal function markers, hematologic parameters, and genetic polymorphisms to enhance predictive accuracy. Integration of machine learning and digital health tools, such as the Universal Clinician Device (UCD) and the mAFA-II mobile application, was also examined for their role in improving anticoagulation safety and adherence.Expert opinion: The future of bleeding risk assessment lies in AI-driven, real-time risk prediction models adapting to dynamic patient profiles. Enhanced integration of digital health solutions and learning health systems will minimize adverse events while optimizing stroke prevention. Future research should prioritize the validation and standardization of these novel tools.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"303-315"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0